Adia Nutrition Business Summary

Adia Nutrition, Inc. (ADIA) operates a vertically integrated healthcare model focused on regenerative medicine, advanced biologics, and premium nutritional supplements. The company generates revenue through a diversified stream of clinical service fees, direct-to-consumer and B2B product sales, insurance-billable wound care treatments, and strategic equity stakes in aligned wellness ventures. Its operations are organized into three primary segments: Adia Med, which manages a growing national network of clinics specializing in stem cell therapies and orthopedic repair; Adia Labs, the regenerative product division distributing flagship therapies like AdiaVita and AdiaLink; and Biolete, a supplement line featuring mushroom-infused and high-protein functional beverages. Positioned as an emerging leader in the regenerative space, ADIA competes with firms such as ZIVO Bioscience, Inc., Upexi, Inc., and Pendulum, distinguishing itself through its transition to full SEC reporting status and its dual-track focus on both clinical research and retail wellness products. Originally founded by April Nugent and Jenny Angeloff Singhal, the company is currently led by CEO Larry Powalisz, who has overseen a transformative period of triple-digit revenue growth and the company’s 2026 transition to a fully reporting SEC registrant. The executive team was recently bolstered by the January 2026 appointment of Dawn Bell as Chief Revenue Officer, bringing over 15 years of medical device and pharmaceutical sales strategy to the firm, and Dr. Brian Browning, who serves as Lead Physician for orthopedic treatments. Scientific and clinical oversight is provided by a robust Board of Medical Directors chaired by Dr. Monica Sher and including notable oncologist Dr. Kalpesh Barot. Following the effectiveness of its Form 10 in February 2026, the company is actively pursuing a NASDAQ Capital Market uplisting, a move designed to attract institutional investors and support its ambitious 2026 clinical trial pipeline for autism and rheumatoid arthritis.